Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02435849
Title Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

childhood B-cell acute lymphoblastic leukemia

B-cell acute lymphoblastic leukemia

Therapies

Tisagenlecleucel

Age Groups: adult | child
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

Facility Status City State Zip Country Details
Childrens Hospital Los Angeles SC CTL019 Los Angeles California 90027 United States Details
Stanford University Medical Center SC - Stanford California 94304 United States Details
Children's Healthcare of Atlanta SC CTL019 Atlanta Georgia 30342 United States Details
University of Michigan SC Ann Arbor Michigan 48109-2800 United States Details
University of Minnesota SC Minneapolis Minnesota 55455 United States Details
Mercy Children's Kansas University Kansas City Missouri 64108 United States Details
Duke Unversity Medical Center Durham North Carolina 27705 United States Details
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229-3039 United States Details
Oregon Health & Science University Doernbecher Children's Hosp. Portland Oregon 97239-3098 United States Details
The Childrens Hospital of Philadelphia CHOP Philadelphia Pennsylvania 19104 United States Details
Children's Medical Center of Dallas SC Dallas Texas 75235 United States Details
University of Utah Salt Lake City Utah 84108 United States Details
University of Wisconsin Hospital and Clinics Madison Wisconsin 53792 United States Details
Novartis Investigative Site Parkville Victoria 3052 Australia Details
Novartis Investigative Site Wien A 1090 Austria Details
Novartis Investigative Site Gent 9000 Belgium Details
Novartis Investigative Site Toronto Ontario M5G 1X8 Canada Details
Novartis Investigative Site Montreal Quebec H3T 1C5 Canada Details
Novartis Investigative Site Paris Cedex 10 Cedex 10 75475 France Details
Novartis Investigative Site Paris Cedex 75019 France Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Monza MB 20900 Italy Details
Novartis Investigative Site Kyoto 606 8507 Japan Details
Novartis Investigative Site Oslo 0424 Norway Details
Novartis Investigative Site Esplugues de Llobregat Barcelona 08950 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field